Especially in relation to genes associated with the mTOR pathway, considering the approved targeted therapies for tuberous sclerosis [36], future gene therapies [37] targeting these genes or their pathways could offer new strategies for disease-modifying treatments in mTLE. This evidence concerns the gene MTOR and tuberous sclerosis.